Estradiol Protects Female ApoE KO Mice against Western-Diet-Induced Non-Alcoholic Steatohepatitis

Autor(es)

Araujo, Layanne C. C. ; Cruz, Alessandra G. ; Camargo, Felipe N. ; Sucupira, Felipe G. ; Moreira, Gabriela V. ; Matos, Sandro L. ; Amaral, Andressa G. ; Murata, Gilson Masahiro ; Carvalho, Carla R. O. ; Camporez, Joao Paulo

• Tipo de documento: Artigo Científico
• Fonte: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES; v. 24, n. 12, p. 15-pg., 2023-06-01.

Resumo

The prevalence of non-alcoholic fatty liver disease (NAFLD) and its severe form, non-alcoholic steatohepatitis (NASH), is higher in men than in women of reproductive age, and postmenopausal women are especially susceptible to developing the disease. Aim: we evaluated if female apolipoprotein E (ApoE) KO mice were protected against Western-diet (WD)-induced NASH. Methods: Female ovariectomized (OVX) ApoE KO mice or sham-operated (SHAM) mice were fed either a WD or a regular chow (RC) for 7 weeks. Additionally, OVX mice fed a WD were treated with either estradiol (OVX + E2) or vehicle (OVX). Results: Whole-body fat, plasma glucose, and plasma insulin were increased and associated with increased glucose intolerance in OVX mice fed a WD (OVX + WD). Plasma and hepatic triglycerides, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) hepatic enzymes were also increased in the plasma of OVX + WD group, which was associated with hepatic fibrosis and inflammation. Estradiol replacement in OVX mice reduced body weight, body fat, glycemia, and plasma insulin associated with reduced glucose intolerance. Treatment also reduced hepatic triglycerides, ALT, AST, hepatic fibrosis, and inflammation in OVX mice. Conclusions: These data support the hypothesis that estradiol protects OVX ApoE KO mice from NASH and glucose intolerance. (AU)

• Processo FAPESP: 19/18965-9 - Efeito do aumento da expressão por vírus adeno associado do receptor de estrogênio alfa sobre o metabolismo hepático
• Beneficiário: Felipe Nunes de Camargo
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica
• Processo FAPESP: 18/04956-5 - Impacto do receptor de estrogênio alpha na Doença Hepática Gordurosa não Alcoólica e metabolismo energético do fígado
• Beneficiário: João Paulo Gabriel Camporez
• Modalidade de apoio: Auxílio à Pesquisa - Jovens Pesquisadores
• Processo FAPESP: 20/09094-1 - Impacto da inibição de galectina-3 sobre a resistência hepática à insulina e metabolismo energético na Esteato-Hepatite Não Alcoólica
• Beneficiário: Layanne Cabral da Cunha Araujo
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 21/02638-9 - Impacto do receptor de estrogênio alpha na doença hepática gordurosa não alcoólica e metabolismo energético do fígado
• Beneficiário: Felipe Garcia da Silva Sucupira
• Modalidade de apoio: Bolsas no Brasil - Mestrado